MedTrace Logo

CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

NCT07388277 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Conditions

  • Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions

DRUG

CC-97540

Intravenous infusion

DRUG

Lymphodepletion Chemotherapy

Intravenous infusion of cyclophosphamide and fludarabine

Sponsors & Collaborators

Principal Investigators

  • Sebastian Unizony, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-09
Primary Completion
2028-12-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07388277 on ClinicalTrials.gov